专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20070010526A1 Therapeutic isoquinoline compounds 审中-公开
标题翻译：治疗异喹啉化合物
公开(公告)号：US20070010526A1
公开(公告)日：2007-01-11
申请号：US10494424
申请日：2002-11-01
申请人： Markus Haeberlein , Christof Angst , Daniel Hill , Robert Jacobs , Gary Moore , Edward Pierson , Ashokkumar Shenvi
发明人： Markus Haeberlein , Christof Angst , Daniel Hill , Robert Jacobs , Gary Moore , Edward Pierson , Ashokkumar Shenvi
IPC分类号： A61K31/496 , A61K31/4709 , C07D403/02 , C07D401/02
CPC分类号： C07D401/04 , C07D217/04 , C07D217/06 , C07D401/12 , C07D405/06 , C07D413/10 , C07D413/12 , C07D417/12
摘要： Provided herein is a compound of the formula (I), wherein said compounds are useful for the treatment of psychiatric disorders including but not limited to depression, generalized anxiety, eating disorders, dementia, panic disorder, and sleep disorders. The compounds may also be useful in the treatment of gastrointestinal disorders, cardiovascular regulation, motor disorders, endocrine disorders, vasospasm and sexual dysfunction. The compounds are 5HT1B and 5HT1D antagonists.
摘要翻译：本文提供了式（I）的化合物，其中所述化合物可用于治疗精神障碍，包括但不限于抑郁症，广泛性焦虑症，进食障碍，痴呆症，惊恐障碍和睡眠障碍。该化合物还可用于治疗胃肠道疾病，心血管调节，运动障碍，内分泌障碍，血管痉挛和性功能障碍。该化合物是5HT 1B和5HT 1D 1拮抗剂。

2. 发明申请

US20090170851A1 Chroman Compounds 审中-公开
标题翻译：色甘酸化合物
公开(公告)号：US20090170851A1
公开(公告)日：2009-07-02
申请号：US12403553
申请日：2009-03-13
申请人： Peter Bernstein , Daniel Hill , David Nugiel , Edward Pierson , Ashokkumar Shenvi , Robert Jacobs
发明人： Peter Bernstein , Daniel Hill , David Nugiel , Edward Pierson , Ashokkumar Shenvi , Robert Jacobs
IPC分类号： A61K31/5377 , A61P25/22
CPC分类号： C07D311/66
摘要： Compounds according to Formula (I): wherein R1, R2, R3, and R4 are as defined in the specification, pharmaceutically-acceptable salts, methods of making, pharmaceutical compositions containing and methods for using the same.
摘要翻译：根据式（I）的化合物：其中R 1，R 2，R 3和R 4如本说明书中所定义，药学上可接受的盐，制备方法，药物组合物及其使用方法。

3. 发明申请

US20070185107A1 Chroman compounds 审中-公开
标题翻译：色甘酸化合物
公开(公告)号：US20070185107A1
公开(公告)日：2007-08-09
申请号：US11592686
申请日：2006-11-03
申请人： Peter Bernstein , Daniel Hill , David Nugiel , Edward Pierson , Ashokkumar Shenvi , Robert Jacobs
发明人： Peter Bernstein , Daniel Hill , David Nugiel , Edward Pierson , Ashokkumar Shenvi , Robert Jacobs
IPC分类号： A61K31/5377 , A61K31/497 , C07D413/14 , C07D405/14
CPC分类号： C07D311/66
摘要： Compounds according to Formula (I): wherein R1, R2, R3, and R4 are as defined in the specification, pharmaceutically-acceptable salts, methods of making, pharmaceutical compositions containing and methods for using the same.
摘要翻译：根据式（I）的化合物：其中R 1，R 2，R 3和R 4均为如本说明书中所定义的药学上可接受的盐，制备方法，含药物组合物及其使用方法。

4. 发明申请

US20080076752A1 Novel Lactams And Uses Thereof 审中-公开
标题翻译：新颖的内华达及其用途
公开(公告)号：US20080076752A1
公开(公告)日：2008-03-27
申请号：US11844451
申请日：2007-08-24
申请人： Christopher Becker , Bruce Dembofsky , Robert Jacobs , James Kang , Cyrus Ohnmacht , James Rosamond , Ashokkumar Shenvi , Thomas Simpson , James Woods
发明人： Christopher Becker , Bruce Dembofsky , Robert Jacobs , James Kang , Cyrus Ohnmacht , James Rosamond , Ashokkumar Shenvi , Thomas Simpson , James Woods
IPC分类号： A61K31/554 , A61P25/28
CPC分类号： C07K5/06034 , A61K38/00 , C07D223/16 , C07D267/10 , C07D267/14 , C07D281/06 , C07D281/10 , C07D405/04 , C07D417/12 , C07D417/14 , C07K5/06026 , C07K5/06191
摘要： Compounds having the formula (I) pharmaceutical compositions containing them and their methods of use for the treatment of neurological disorders related to amyloid β protein production and neurological disorders such as Alzheimer's disease. These compounds inhibit γ secretase and thereby inhibit the production of amyloid β protein, thereby acting to prevent the formation of neurological deposits of amyloid protein.
摘要翻译：具有式（I）的药物组合物和含有它们的药物组合物及其用于治疗与淀粉样蛋白β蛋白生产和神经障碍如阿尔茨海默病有关的神经障碍的方法。这些化合物抑制γ分泌酶，从而抑制淀粉样蛋白β蛋白的产生，从而起到防止淀粉样蛋白的神经沉积的形成的作用。

5. 发明申请

US20060089346A1 Novel lactams and uses thereof 失效
标题翻译：新型内酰胺及其用途
公开(公告)号：US20060089346A1
公开(公告)日：2006-04-27
申请号：US10528640
申请日：2003-10-02
申请人： Christopher Becker , Bruce Dembofsky , Robert Jacobs , James Kang , Cyrus Ohnmacht , James Rosamond , Ashokkumar Shenvi , Thomas Simpson , James Woods
发明人： Christopher Becker , Bruce Dembofsky , Robert Jacobs , James Kang , Cyrus Ohnmacht , James Rosamond , Ashokkumar Shenvi , Thomas Simpson , James Woods
IPC分类号： A61K31/554 , A61K31/55 , A61K31/551
CPC分类号： C07K5/06034 , A61K38/00 , C07D223/16 , C07D267/10 , C07D267/14 , C07D281/06 , C07D281/10 , C07D405/04 , C07D417/12 , C07D417/14 , C07K5/06026 , C07K5/06191
摘要： Compounds having the formula (1) pharmaceutical compositions containing them and their methods of use for the treatment of neurological disorders related to amyloid B protein production and neurological disorders such as Alzheimer's disease. These compounds inhibit γ secretase and thereby inhibit the production of amyloid β protein, thereby acting to prevent the formation of neurological deposits of amyloid protein.
摘要翻译：具有式（1）的药物组合物及其用于治疗与淀粉样蛋白B蛋白质产生和神经障碍如阿尔茨海默病相关的神经障碍的方法。这些化合物抑制γ分泌酶，从而抑制淀粉样蛋白β蛋白的产生，从而起到防止淀粉样蛋白的神经沉积的形成的作用。

6. 发明申请

US20070021406A1 New neurokinin antagonists for use as medicaments 失效
标题翻译：用作药物的新型神经激肽拮抗剂
公开(公告)号：US20070021406A1
公开(公告)日：2007-01-25
申请号：US11042752
申请日：2005-01-24
申请人： Jeffrey Albert , Peter Bernstein , Cyrus Ohnmacht , Keith Russell , Ashokkumar Shenvi
发明人： Jeffrey Albert , Peter Bernstein , Cyrus Ohnmacht , Keith Russell , Ashokkumar Shenvi
IPC分类号： A61K31/454 , C07D417/14
CPC分类号： C07D413/06 , C07D273/00 , C07D413/12 , C07D413/14
摘要： The present application relates to internally cyclized naphthamide compounds of the formula Ia (wherein R1a, R1b, R1c, R2, R3, R4, R5, R6, R7, R8, X1, X2, Y, Z, and n are as defined herein), which are useful, for example, for antagonizing the pharmacological actions of the neurokinin 1 (NK1) receptor. In particular, these compounds are useful in the treatment of diseases in which Substance P is involved such as, for example, major depressive disorder, severe anxiety disorders, stress disorders, major depressive disorder with anxiety, eating disorders, bipolar disorder, substance use disorder, schizophrenic disorders, psychotic disorders, movement disorders, cognitive disorders, depression and/or anxiety, mania or hypomania, aggressive behaviour, obesity, rheumatoid arthritis, Alzheimer's disease, cancer, oedema, allergic rhinitis, inflammation, pain, gastrointestinal-hypermotility, Huntington's disease, chronic obstructive pulmonary disorder (COPD), hypertension, migraine, bladder hypermotility, and urticaria.
摘要翻译：本申请涉及式Ia的其中环化的萘甲酰胺化合物（其中R 1a，R 1b，R 1c，R i，R 2， R 3，R 4，R 4，R 5，R 6，R 7， R 8，X 1，X 1，X 2，Y，Z和n如本文所定义），它们是有用的例如，用于拮抗神经激肽1（NK 1 H 2）受体的药理作用。特别地，这些化合物可用于治疗涉及物质P的疾病，例如重度抑郁障碍，严重焦虑障碍，应激障碍，焦虑症重度抑郁障碍，进食障碍，双相情感障碍，物质使用障碍精神分裂症，精神病，运动障碍，认知障碍，抑郁和/或焦虑，躁狂或轻躁狂，侵略行为，肥胖症，类风湿性关节炎，阿尔茨海默氏病，癌症，水肿，过敏性鼻炎，炎症，疼痛，胃肠超运动，亨廷顿氏症疾病，慢性阻塞性肺疾病（COPD），高血压，偏头痛，膀胱过度运动和荨麻疹。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式